Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI lends a hand in the operating room to stop bleeding faster

NCT ID NCT07495137

Symptom relief Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study tests whether a real-time artificial intelligence system can help doctors find and stop bleeding faster during a minimally invasive surgery called endoscopic submucosal dissection (ESD), used to remove early-stage digestive tract cancers. About 160 patients will be randomly assigned to have the surgery with or without AI assistance. The main goal is to see if the AI shortens the time it takes to stop each bleed, and the study will also track complications and total surgery time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Artificial intelligence software that identifies bleeding points in real time during endoscopy
What this could lead to
If it works, this could make a common cancer-removal surgery safer and faster by helping doctors stop bleeding more quickly.
What could go wrong
This is an early-stage trial with only 160 people, so results may not apply to all patients. The AI might not work well in every case or could miss some bleeding points.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Aged 18-80 years; 2. Lesions meet the indications for ESD treatment of the esophagus, stomach, or colorectum according to relevant guidelines; 3. Anticoagulant drugs have been suspended according to relevant guidelines; 4. Patients with American Society of Anesthesiologists (ASA) classification Grade I or II; 5. Patients who voluntarily sign the informed consent form. Exclusion Criteria 1. Patients with severe cardiopulmonary diseases, coagulation dysfunction or other severe comorbidities that may increase surgical risks; 2. Patients undergoing dialysis treatment; 3. Pregnant or lactating women; 4. Deemed unsuitable for participation in this study by the principal investigator or other researchers.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endoscopic submucosal dissection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

precancerous condition

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endoscopic submucosal dissection Endoscopic submucosal dissection (ESD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.